239 related articles for article (PubMed ID: 23435461)
21. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia.
Rossi D; Spina V; Bomben R; Rasi S; Dal-Bo M; Bruscaggin A; Rossi FM; Monti S; Degan M; Ciardullo C; Serra R; Zucchetto A; Nomdedeu J; Bulian P; Grossi A; Zaja F; Pozzato G; Laurenti L; Efremov DG; Di-Raimondo F; Marasca R; Forconi F; Del Poeta G; Gaidano G; Gattei V
Blood; 2013 Jun; 121(24):4902-5. PubMed ID: 23637131
[TBL] [Abstract][Full Text] [Related]
22. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2.
Strefford JC; Sutton LA; Baliakas P; Agathangelidis A; Malčíková J; Plevova K; Scarfó L; Davis Z; Stalika E; Cortese D; Cahill N; Pedersen LB; di Celle PF; Tzenou T; Geisler C; Panagiotidis P; Langerak AW; Chiorazzi N; Pospisilova S; Oscier D; Davi F; Belessi C; Mansouri L; Ghia P; Stamatopoulos K; Rosenquist R
Leukemia; 2013 Nov; 27(11):2196-9. PubMed ID: 23558524
[TBL] [Abstract][Full Text] [Related]
23. A reduced panel of eight genes (ATM, SF3B1, NOTCH1, BIRC3, XPO1, MYD88, TNFAIP3, and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia.
Chauzeix J; Pastoret C; Donaty L; Gachard N; Fest T; Feuillard J; Rizzo D
Int J Lab Hematol; 2021 Aug; 43(4):683-692. PubMed ID: 33325634
[TBL] [Abstract][Full Text] [Related]
24. Prognostic correlation of NOTCH1 and SF3B1 mutations with chromosomal abnormalities in chronic lymphocytic leukemia patients.
Sadria R; Motamed N; Saberi Anvar M; Mehrabani Yeganeh H; Poopak B
Cancer Rep (Hoboken); 2023 Mar; 6(3):e1757. PubMed ID: 36411516
[TBL] [Abstract][Full Text] [Related]
25. IMMUNOPHENOTYPE OF LEUKEMIC CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH NOTCH1 AND SF3B1 GENE MUTATIONS.
Golyarnik N; Абраменко І; Movchan G; Martina Z; Dyagil I; Chumak A; Bazyka D
Exp Oncol; 2023 Dec; 45(3):322-327. PubMed ID: 38186023
[TBL] [Abstract][Full Text] [Related]
26. Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia.
Ouillette P; Saiya-Cork K; Seymour E; Li C; Shedden K; Malek SN
Clin Cancer Res; 2013 Jun; 19(11):2893-904. PubMed ID: 23620403
[TBL] [Abstract][Full Text] [Related]
27. New boys in town: prognostic role of SF3B1, NOTCH1 and other cryptic alterations in chronic lymphocytic leukemia and how it works.
Filip AA
Leuk Lymphoma; 2013 Sep; 54(9):1876-81. PubMed ID: 23343182
[TBL] [Abstract][Full Text] [Related]
28. Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53.
Zent CS; Burack WR
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):119-24. PubMed ID: 25696844
[TBL] [Abstract][Full Text] [Related]
29. Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.
Sutton LA; Ljungström V; Mansouri L; Young E; Cortese D; Navrkalova V; Malcikova J; Muggen AF; Trbusek M; Panagiotidis P; Davi F; Belessi C; Langerak AW; Ghia P; Pospisilova S; Stamatopoulos K; Rosenquist R
Haematologica; 2015 Mar; 100(3):370-6. PubMed ID: 25480502
[TBL] [Abstract][Full Text] [Related]
30. Predicting treatment outcomes in CLL.
Wiestner A
Blood; 2014 May; 123(21):3212-4. PubMed ID: 24855188
[TBL] [Abstract][Full Text] [Related]
31. SF3B1 mutations in chronic lymphocytic leukemia.
Wan Y; Wu CJ
Blood; 2013 Jun; 121(23):4627-34. PubMed ID: 23568491
[TBL] [Abstract][Full Text] [Related]
32. Analysis of SF3B1 mutations in monoclonal B-cell lymphocytosis.
Greco M; Capello D; Bruscaggin A; Spina V; Rasi S; Monti S; Ciardullo C; Cresta S; Fangazio M; Gaidano G; Foà R; Rossi D
Hematol Oncol; 2013 Mar; 31(1):54-5. PubMed ID: 22461140
[No Abstract] [Full Text] [Related]
33. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.
Rossi D; Bruscaggin A; Spina V; Rasi S; Khiabanian H; Messina M; Fangazio M; Vaisitti T; Monti S; Chiaretti S; Guarini A; Del Giudice I; Cerri M; Cresta S; Deambrogi C; Gargiulo E; Gattei V; Forconi F; Bertoni F; Deaglio S; Rabadan R; Pasqualucci L; Foà R; Dalla-Favera R; Gaidano G
Blood; 2011 Dec; 118(26):6904-8. PubMed ID: 22039264
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.
Dreger P; Döhner H; Ritgen M; Böttcher S; Busch R; Dietrich S; Bunjes D; Cohen S; Schubert J; Hegenbart U; Beelen D; Zeis M; Stadler M; Hasenkamp J; Uharek L; Scheid C; Humpe A; Zenz T; Winkler D; Hallek M; Kneba M; Schmitz N; Stilgenbauer S;
Blood; 2010 Oct; 116(14):2438-47. PubMed ID: 20595516
[TBL] [Abstract][Full Text] [Related]
35. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.
Rossi D; Rasi S; Fabbri G; Spina V; Fangazio M; Forconi F; Marasca R; Laurenti L; Bruscaggin A; Cerri M; Monti S; Cresta S; Famà R; De Paoli L; Bulian P; Gattei V; Guarini A; Deaglio S; Capello D; Rabadan R; Pasqualucci L; Dalla-Favera R; Foà R; Gaidano G
Blood; 2012 Jan; 119(2):521-9. PubMed ID: 22077063
[TBL] [Abstract][Full Text] [Related]
36. Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1.
Tausch E; Beck P; Schlenk RF; Jebaraj BJ; Dolnik A; Yosifov DY; Hillmen P; Offner F; Janssens A; Babu GK; Grosicki S; Mayer J; Panagiotidis P; McKeown A; Gupta IV; Skorupa A; Pallaud C; Bullinger L; Mertens D; Döhner H; Stilgenbauer S
Haematologica; 2020 Oct; 105(10):2440-2447. PubMed ID: 33054084
[TBL] [Abstract][Full Text] [Related]
37. IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events.
Rizzo D; Chauzeix J; Trimoreau F; Woillard JB; Genevieve F; Bouvier A; Labrousse J; Poli C; Guerin E; Dmytruk N; Remenieras L; Feuillard J; Gachard N
Leukemia; 2015 Feb; 29(2):337-45. PubMed ID: 24943833
[TBL] [Abstract][Full Text] [Related]
38. Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia.
Schwaederlé M; Ghia E; Rassenti LZ; Obara M; Dell'Aquila ML; Fecteau JF; Kipps TJ
Leukemia; 2013 Apr; 27(5):1214-7. PubMed ID: 23337928
[No Abstract] [Full Text] [Related]
39. CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.
Dal Bo M; Bulian P; Bomben R; Zucchetto A; Rossi FM; Pozzo F; Tissino E; Benedetti D; Bittolo T; Nanni P; Cattarossi I; Zaina E; Chivilò H; Degan M; Zaja F; Pozzato G; Chiarenza A; Di Raimondo F; Del Principe MI; Del Poeta G; Rossi D; Gaidano G; Gattei V
Leukemia; 2016 Oct; 30(10):2011-2018. PubMed ID: 27109509
[TBL] [Abstract][Full Text] [Related]
40.
Pozzo F; Bittolo T; Tissino E; Vit F; Vendramini E; Laurenti L; D'Arena G; Olivieri J; Pozzato G; Zaja F; Chiarenza A; Di Raimondo F; Zucchetto A; Bomben R; Rossi FM; Del Poeta G; Dal Bo M; Gattei V
Haematologica; 2021 Dec; 106(12):3125-3135. PubMed ID: 33121237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]